Skip to main content
Premium Trial:

Request an Annual Quote

Ensemble Discovery, Roche Collaborate on EGFR Assays for Cancer Drug Response

NEW YORK (GenomeWeb news) – Ensemble Discovery said today that it has extended an existing collaboration with Roche that is using Ensemble’s diagnostic assays to analyze proteins in cancer tissues in an effort to develop new treatment tools.
Under the extended agreement, the companies aim to develop product prototypes that detect EGFR receptor dimers in cancer samples. Ensemble said that it will develop a test that will correlate particular EGFR family dimer patterns with the efficacy of certain anti-cancer drugs.  
Ensemble said this technology could help to identify new targeted drug combinations and the cancer patients who are likely to respond to a particular therapy targeted against the EGFR family.
Six drugs are currently on the market that attack the EGFR family, and others are in clinical trials, but these drugs are only effective in a subset of patients for whom they are indicated. Why these drugs do not work for more patients “is not well understood and needs further investigation with the aim of optimizing clinical study programs and future treatments,” the company said.
Roche and Ensemble began their pertnership in July 2007. The original collaboration "demonstrated the ability of our assays to detect receptor dimers in human pathological samples," said David Livingston, senior VP and head of biodetection at Ensemble.
Under the new agreement, the companies plan to extend the panel of assays against various members of the EGFR family and advance those assays into clinical studies, he said. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more